Recent Updates
Recently added Catalysts
XTNT Positive Sentiment

Xtant Medical Reports Second Quarter 2025 Financial Results

Tuesday, August 12, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xtant Medical Holdings, Inc. reported its financial results for the second quarter of 2025, highlighting a total revenue of $35.4 million, which reflects an 18% increase compared to the previous year. The company achieved positive net income, adjusted EBITDA, and operating cash flow. Additionally, Xtant raised its revenue guidance for FY25 to a range of $131-$135 million, indicating expected growth of 11%-15% over FY24.
Price reaction · baseline $0.5873 (2025-08-11 close) · hit pre-market · clean, no other XTNT news in the window
day 0 close · peak
+14.1%
day 1
+10.6%
day 3
+7.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Total revenue increased by 18% year-over-year.
  • The company reported positive net income and adjusted EBITDA.
  • Operating cash flow was positive.
  • FY25 revenue guidance raised to $131-$135 million.

Full Press Release Details

Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance to $131-$135 Million , Representing Growth of 11%-15% over FY24 BELGRADE, Mont. , Aug. 12, 2025 /PRNewswire/ — Xtant Medical Holdings, Inc.

Frequently Asked Questions

What was Xtant Medical's total revenue for Q2 2025?

Xtant Medical reported a total revenue of $35.4 million for Q2 2025.

How much did Xtant Medical's revenue increase year-over-year?

The revenue increased by 18% year-over-year.

What is the new revenue guidance for FY25?

The new revenue guidance for FY25 is between $131 million and $135 million.

Did Xtant Medical report a positive net income?

Yes, Xtant Medical reported a positive net income for the quarter.

ShareAdd on Google
Tags: XTNT Viatris Investor Conferences Healthcare Xtant Medical financial results Q2 2025 revenue growth FY25 guidance
Last updated: Aug 12, 2025

Biotech snapshot

Cash runway
$10M liquidity · $2M/mo burn
~4 mo
High dilution risk